PAR PHARMACEUTICAL COMPANIES, INC. Research and Development Expense
PAR PHARMACEUTICAL COMPANIES, INC. reported Research and Development Expense of $28.58 million for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2015-08-06
- PAR PHARMACEUTICAL COMPANIES, INC. research and development expense for the quarter ending 2015-06-30 was $28.58M, a 0.43% increase year-over-year.
- PAR PHARMACEUTICAL COMPANIES, INC. research and development expense for the quarter ending 2015-03-31 was $26.85M, a 22.45% decline year-over-year.
- PAR PHARMACEUTICAL COMPANIES, INC. research and development expense for the quarter ending 2014-09-30 was $26.48M, a 2.81% decline year-over-year.
- PAR PHARMACEUTICAL COMPANIES, INC. research and development expense for the quarter ending 2014-06-30 was $28.45M, a 10.24% increase year-over-year.
- PAR PHARMACEUTICAL COMPANIES, INC. research and development expense for fiscal 2011 was $46.54M, a 7.61% decline from fiscal 2010.
- PAR PHARMACEUTICAL COMPANIES, INC. research and development expense for fiscal 2010 was $50.37M, a 28.38% increase from fiscal 2009.
- PAR PHARMACEUTICAL COMPANIES, INC. research and development expense for fiscal 2009 was $39.23M.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2015-06-30 | $28.58M 10-Q · filed 2015-08-06 | $55.42M 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $26.85M 10-Q · filed 2015-05-11 | ||||
| 2014-09-30 | $26.48M 10-Q · filed 2014-11-12 | $54.94M derived: sum of 2 quarters · filed 2015-08-06 | $89.54M 10-Q · filed 2014-11-12 | ||
| 2014-06-30 | $28.45M 10-Q · filed 2015-08-06 | $63.05M 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | $34.62M 10-Q · filed 2015-05-11 | ||||
| 2013-09-30 | $27.25M 10-Q · filed 2014-11-12 | $53.06M derived: sum of 2 quarters · filed 2014-11-12 | $73.28M 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | $25.81M 10-Q · filed 2014-08-11 | $46.03M 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | $20.22M 10-Q · filed 2014-05-15 | ||||
| 2012-06-30 | $20.72M 10-Q · filed 2012-08-02 | $50.62M 10-Q · filed 2012-08-02 | $68.76M derived: sum of 3 quarters · filed 2012-08-02 | $78.37M derived: sum of 4 quarters · filed 2012-08-02 | |
| 2012-03-31 | $29.90M 10-Q · filed 2012-05-08 | $48.04M derived: sum of 2 quarters · filed 2012-05-08 | $57.65M derived: sum of 3 quarters · filed 2012-05-08 | $65.73M derived: sum of 4 quarters · filed 2012-08-02 | |
| 2011-12-31 | $18.14M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $27.75M derived: sum of 2 quarters · filed 2012-02-28 | $35.83M derived: sum of 3 quarters · filed 2012-08-02 | $46.54M 10-K · filed 2012-02-28 | |
| 2011-09-30 | $9.61M 10-Q · filed 2011-11-02 | $17.69M derived: sum of 2 quarters · filed 2012-08-02 | $28.40M 10-Q · filed 2011-11-02 | $28.90M derived: sum of 4 quarters · filed 2012-08-02 | |
| 2011-06-30 | $8.08M 10-Q · filed 2012-08-02 | $18.79M 10-Q · filed 2012-08-02 | $19.29M derived: sum of 3 quarters · filed 2012-08-02 | $29.43M derived: sum of 4 quarters · filed 2012-08-02 | |
| 2011-03-31 | $10.71M 10-Q · filed 2012-05-08 | $11.21M derived: sum of 2 quarters · filed 2012-05-08 | $21.36M derived: sum of 3 quarters · filed 2012-05-08 | $44.02M derived: sum of 4 quarters · filed 2012-05-08 | |
| 2010-12-31 | $500.00K 10-Q · filed 2011-08-03 | $10.64M derived: sum of 2 quarters · filed 2011-11-02 | $33.30M derived: sum of 3 quarters · filed 2011-11-02 | $50.37M 10-K · filed 2012-02-28 | |
| 2010-09-30 | $10.14M 10-Q · filed 2011-11-02 | $32.80M derived: sum of 2 quarters · filed 2011-11-02 | $37.46M 10-Q · filed 2011-11-02 | ||
| 2010-06-30 | $22.66M 10-Q · filed 2011-08-03 | $27.31M 10-Q · filed 2011-08-03 | |||
| 2010-03-31 | $4.65M 10-Q/A · filed 2011-05-06 | ||||
| 2009-12-31 | $6.50M 10-Q · filed 2011-11-02 | $39.23M 10-K · filed 2012-02-28 |